Royalty Pharma PLC Class A

RPRX: XNAS (USA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
%>LOCK|xnXVtLOCK|<!B?J%TM

Royalty Pharma Earnings: Optimistic Guidance as Vertex Dispute Enters Resolution Process

Royalty Pharma increased its portfolio receipts 20% year over year in the second quarter of 2025, announced a partnership with Revolution Medicines worth up to $2 billion, and completed an acquisition of its external manager with overwhelming shareholder support.

Sponsor Center